Gastric Cancer
Conditions
Interventions
extensive intra-peritoneal lavage for patients with CY or Stamp positve
Sponsors
Osaka City University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Histologically diagnosed with gastric cancer (pap, tub1, tub2, por1, por2, sig, muc, or a special type) based on endoscopic biopsy from the primary gastric lesion. Positive peritoneal lavage cytology or gastric wall imprint cytology, but no evidence of distant metastasis; eligible for R0/1 resection via gastrectomy with D2 lymph node dissection (including total or distal gastrectomy, and laparoscopic surgery). General anesthesia combined with epidural anesthesia will be used. Esophageal invasion is within 3 cm and no thoracotomy has been performed. Aged between 20 and 80 years. Performance Status (ECOG) of 0 or 1. No prior history of chemotherapy (including endocrine therapy) or radiotherapy, including for other malignancies. Meets all of the following laboratory criteria (based on the most recent preoperative test results within 56 days prior to enrollment; tests conducted on the same weekday up to 8 weeks before enrollment are acceptable): Data regarding WBC, Plt, AST, ALT, T-Bil, and Cre Written informed consent for participation in the study has been obtained from the patient.
Exclusion criteria
Exclusion criteria: Women who are pregnant or breastfeeding, or who may be pregnant. Individuals with psychiatric disorders or symptoms deemed unable to participate in the study. Individuals receiving continuous systemic administration of steroids (oral or intravenous). Individuals with a history of myocardial infarction within the past six months or with unstable angina. Individuals with uncontrolled hypertension. Individuals undergoing insulin therapy or with uncontrolled diabetes. Individuals with respiratory diseases requiring continuous oxygen therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival, Recurrence site, postoperative adverse events | — |
Countries
Japan
Contacts
Public ContactYuichiro Miki
Osaka City University Department of Gastroenterological Surgery
Outcome results
None listed